FDA Removes Clinical Hold for Dynavax's (DVAX) IND HEPLISAV
Up)
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease. HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
As a result of the FDA's decision, Dynavax expects to initiate a Phase 3 trial in chronic kidney disease patients in the near-term. Dynavax also plans to initiate a Phase 3 lot-to-lot consistency trial in adults over 40 years of age in early 2010.
[SM]
As a result of the FDA's decision, Dynavax expects to initiate a Phase 3 trial in chronic kidney disease patients in the near-term. Dynavax also plans to initiate a Phase 3 lot-to-lot consistency trial in adults over 40 years of age in early 2010.
[SM]
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
